Dermott O’Callaghan, CSO, has 20 years experience in the pharmaceutical industry. His focus has been on early drug discovery in neuroscience with an emphasis on ion channels. He has in-depth experience of numerous drug discovery approaches and technologies ranging from high-throughput screening to pre-clinical candidate selection.  His approach is based on embracing the emerging outward facing drug discovery business models to ensure clients are best placed to capitalise on pre-competition interactions, cloud based open-access data sharing, out-sourced experimental work and new technological advancement.